Table 1.
Summary of the dasatinib treatment results.
| Dasatinib treatment | Number of patients (%) |
|---|---|
| All | 86 (100%) |
| In the 2nd line | 78 (90.7%) |
| In the 3rd line | 8 (9.3%) |
| Response to treatment a | |
| Optimal CyR b | 52 (60.5%) |
| CCyR | 49 (57%) |
| PCyR | 9 (11%) |
| mCyR | 21 (24%) |
| noCyR | 7 (8%) |
| Optimal MR c | 8 (9.3%) |
| CMR | 24 (30%) |
| MMR | 19 (24%) |
| No MR | 37(46%) |
| Progression | 14 (16.3%) |
| Fluid retention | 15 (17.4%) |
|
Incidence
of any hematological complications |
33 (38.4%) |
a
Response to treatment: in the database were included results of the last medical visit for each patient.
b
Optimal CyR: achievement of the complete cytogenetic response within 12 months from treatment start.
c
Optimal MR: achievement of at least the major molecular response within 18 months from treatment start. Only eight patients (9.3%) achieved optimal response, i.e., at least MR3 within 18 months from the start of treatment; other patients achieved CMR and MMR but after 18 months of treatment, therefore they were not included as optimal MR.
Data on the cytogenetic and molecular response as well as the occurrence of treatment side effects are included.